Research and Markets: Gastric Cancer Drug Discoveries: What the Future Holds 2011

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/bba124/gastric_cancer_dru) has announced the addition of the "Gastric Cancer Drug Discoveries: What the Future Holds" report to their offering.

Original analysis of the clinical potential and commercial prospects for companies, launched products and pipeline candidates put into current market context.

The market is set for rapid and significant growth:

There is room for considerable change in the gastric cancer market as improved therapies seek to improve patient outcomes for advanced disease. Over the next seven years, the analyst expects to see the market grow by 133% from US$846 million in 2010, to US$1.97 billion in 2017, with the targeted therapies accounting for most of this growth. While competition amongst these targeted therapies will intensify from 2013/4, Roche will continue to dominate this market with Herceptin, which was recently approved in Japan.

Next generation chemotherapy:

While targeted therapies are expected to grow rapidly, it is chemotherapy agents which are leading the current market. One notable success of recent years is Roche's Xeloda, which is replacing 5-FU in the US and EU, where it has been approved as a first-line treatment in gastric cancer since March 2007. With US patents in force until 2013, Xeloda is the only branded chemotherapeutic for gastric cancer not facing generic competition at present.

Critical Business Insights from this report which:

  • Provides independent, reliable 7-year forecasts, market share and unique product scoring which give you real insights to the current and future business landscape
  • Evaluates the competitive environment - assess winners and losers and know their pipeline content and status
  • Covers major launched products and significant pipeline candidates
  • Identifies promising mid-stage development candidates
  • Forecasts the launch timeframe for new products or indications
  • Summarises current clinical thinking on gastric cancer

To view the reports full table of contents and for more information, please visit http://www.researchandmarkets.com/research/bba124/gastric_cancer_dru.

Source: Espicom Business Intelligence Ltd



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America

INDUSTRY KEYWORDS:   Health  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Belén Garijo, currently CEO of Merck Healthcare, will succeed Stefan Oschmann as the German company's chief exec when his tenure ends in April 2021.

More than 60 researchers and bioethicists called on Pfizer to take time to collect more COVID-19 vaccine safety data, Bloomberg reports. 

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.